Detection of fusion gene transcripts in the blood samples of prostate cancer patients

Abstract Prostate cancer remains one of the most lethal cancers for men in the United States. The study aims to detect fusion transcripts in the blood samples of prostate cancer patients. We analyzed nine fusion transcripts including MAN2A1-FER, SLC45A2-AMACR, TRMT11-GRIK2, CCNH-C5orf30, mTOR-TP53BP...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yan-Ping Yu, Silvia Liu, Joel Nelson, Jian-Hua Luo
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/c4edd5c747814d3bad684fb9ac27e34b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c4edd5c747814d3bad684fb9ac27e34b
record_format	dspace
spelling	oai:doaj.org-article:c4edd5c747814d3bad684fb9ac27e34b2021-12-02T16:46:34ZDetection of fusion gene transcripts in the blood samples of prostate cancer patients10.1038/s41598-021-96528-92045-2322https://doaj.org/article/c4edd5c747814d3bad684fb9ac27e34b2021-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-96528-9https://doaj.org/toc/2045-2322Abstract Prostate cancer remains one of the most lethal cancers for men in the United States. The study aims to detect fusion transcripts in the blood samples of prostate cancer patients. We analyzed nine fusion transcripts including MAN2A1-FER, SLC45A2-AMACR, TRMT11-GRIK2, CCNH-C5orf30, mTOR-TP53BP1, KDM4-AC011523.2, TMEM135-CCDC67, LRRC59-FLJ60017 and Pten-NOLC1147 in the blood samples from 147 prostate cancer patients and 14 healthy individuals, using Taqman RT-PCR and Sanger’s sequencing. Similar analyses were also performed on 25 matched prostate cancer samples for matched-sample evaluation. Eighty-two percent blood samples from the prostate cancer patients were positive for MAN2A1-FER transcript, while 41.5% and 38.8% blood samples from the prostate cancer patients were positive for SLC45A2-AMACR and Pten-NOLC1, respectively. CCNH-c5orf30 and mTOR-TP53BP1 had low detection rates, positive in only 5.4% and 4% of the blood samples from the prostate cancer patients. Only 2 blood samples were positive for KDM4B-AC011523.2 transcript. Overall, 89.8% patients were positive for at least one fusion transcript in their blood samples. The statistical analysis showed varied sensitivity of fusion transcript detection in the blood based on the types of fusions. In contrast, the blood samples from all healthy individuals were negative for the fusion transcripts. Detection of fusion transcripts in the blood samples of the prostate cancer patients may be a fast and cost-effective way to detect prostate cancer.Yan-Ping YuSilvia LiuJoel NelsonJian-Hua LuoNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-6 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Yan-Ping Yu Silvia Liu Joel Nelson Jian-Hua Luo Detection of fusion gene transcripts in the blood samples of prostate cancer patients
description	Abstract Prostate cancer remains one of the most lethal cancers for men in the United States. The study aims to detect fusion transcripts in the blood samples of prostate cancer patients. We analyzed nine fusion transcripts including MAN2A1-FER, SLC45A2-AMACR, TRMT11-GRIK2, CCNH-C5orf30, mTOR-TP53BP1, KDM4-AC011523.2, TMEM135-CCDC67, LRRC59-FLJ60017 and Pten-NOLC1147 in the blood samples from 147 prostate cancer patients and 14 healthy individuals, using Taqman RT-PCR and Sanger’s sequencing. Similar analyses were also performed on 25 matched prostate cancer samples for matched-sample evaluation. Eighty-two percent blood samples from the prostate cancer patients were positive for MAN2A1-FER transcript, while 41.5% and 38.8% blood samples from the prostate cancer patients were positive for SLC45A2-AMACR and Pten-NOLC1, respectively. CCNH-c5orf30 and mTOR-TP53BP1 had low detection rates, positive in only 5.4% and 4% of the blood samples from the prostate cancer patients. Only 2 blood samples were positive for KDM4B-AC011523.2 transcript. Overall, 89.8% patients were positive for at least one fusion transcript in their blood samples. The statistical analysis showed varied sensitivity of fusion transcript detection in the blood based on the types of fusions. In contrast, the blood samples from all healthy individuals were negative for the fusion transcripts. Detection of fusion transcripts in the blood samples of the prostate cancer patients may be a fast and cost-effective way to detect prostate cancer.
format	article
author	Yan-Ping Yu Silvia Liu Joel Nelson Jian-Hua Luo
author_facet	Yan-Ping Yu Silvia Liu Joel Nelson Jian-Hua Luo
author_sort	Yan-Ping Yu
title	Detection of fusion gene transcripts in the blood samples of prostate cancer patients
title_short	Detection of fusion gene transcripts in the blood samples of prostate cancer patients
title_full	Detection of fusion gene transcripts in the blood samples of prostate cancer patients
title_fullStr	Detection of fusion gene transcripts in the blood samples of prostate cancer patients
title_full_unstemmed	Detection of fusion gene transcripts in the blood samples of prostate cancer patients
title_sort	detection of fusion gene transcripts in the blood samples of prostate cancer patients
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/c4edd5c747814d3bad684fb9ac27e34b
work_keys_str_mv	AT yanpingyu detectionoffusiongenetranscriptsinthebloodsamplesofprostatecancerpatients AT silvialiu detectionoffusiongenetranscriptsinthebloodsamplesofprostatecancerpatients AT joelnelson detectionoffusiongenetranscriptsinthebloodsamplesofprostatecancerpatients AT jianhualuo detectionoffusiongenetranscriptsinthebloodsamplesofprostatecancerpatients
_version_	1718383420056272896

Detection of fusion gene transcripts in the blood samples of prostate cancer patients

Ejemplares similares